Literature DB >> 21177919

Evaluation of serum bactericidal antibody assays for Haemophilus influenzae serotype a.

Nadine G Rouphael1, Sarah Satola, Monica M Farley, Karen Rudolph, Daniel S Schmidt, Patricia Gomez-de-León, John B Robbins, Rachel Schneerson, George M Carlone, Sandra Romero-Steiner.   

Abstract

Haemophilus influenzae type a (Hia) is an important pathogen for some American Indian, Alaskan native, and Northern Canada aboriginal populations. Assays to measure serum bactericidal activity (SBA) to Hia have not been developed or validated. Here, we describe two methods for the measurement of SBA: SBA with a viability endpoint (CFU counts) and SBA with a fluorometric endpoint using alamarBlue as the metabolic indicator. Both SBA assays measure Hia-specific functional antibody and correlate with anti-Hia IgG enzyme-linked immunosorbent assay (ELISA) concentration of naturally acquired antibodies.

Mesh：

Substances：

Year:  2010        PMID： 21177919      PMCID： PMC3067367          DOI： 10.1128/CVI.00219-10

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  17 in total

1.  Measurement of serum bactericidal activity specific for Haemophilus influenzae type b by using a chromogenic and fluorescent metabolic indicator.

Authors:  Sandra Romero-Steiner; Willie Spear; Nekeidra Brown; Patricia Holder; Thomas Hennessy; Patricia Gomez De Leon; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

2.  Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies.

Authors:  J B Robbins; J C Parke; R Schneerson; J K Whisnant
Journal:  Pediatr Res       Date:  1973-03       Impact factor: 3.756

3.  PCR for capsular typing of Haemophilus influenzae.

Authors:  T J Falla; D W Crook; L N Brophy; D Maskell; J S Kroll; E R Moxon
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

4.  Randomized trial of the immunogenicity of fractional dose regimens of PRP-T Haemophilus influenzae type b conjugate vaccine.

Authors:  J Fernández; S Balter; J Feris; E Gómez; Z Garib; P L Castellanos; J Sánchez; S Romero-Steiner; O S Levine
Journal:  Am J Trop Med Hyg       Date:  2000-04       Impact factor: 2.345

5.  Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children--United States, 1998-2000.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-03-22       Impact factor: 17.586

6.  Differential complement resistance mediates virulence of Haemophilus influenzae type b.

Authors:  A Sutton; R Schneerson; S Kendall-Morris; J B Robbins
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

7.  Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group.

Authors:  Y Schlesinger; D M Granoff
Journal:  JAMA       Date:  1992-03-18       Impact factor: 56.272

8.  Characterization of the serum antibody response to the capsular polysaccharide of Haemophilus influenzae type b in children with invasive infections.

Authors:  B Trollfors; T Lagergård; B A Claesson; E Thornberg; J Martinell; R Schneerson
Journal:  J Infect Dis       Date:  1992-12       Impact factor: 5.226

9.  Epidemiology of Haemophilus influenzae serotype a, North American Arctic, 2000-2005.

Authors:  Michael G Bruce; Shelley L Deeks; Tammy Zulz; Christine Navarro; Carolina Palacios; Cheryl Case; Colleen Hemsley; Tom Hennessy; Andre Corriveau; Bryce Larke; Isaac Sobel; Marguerite Lovgren; Carolynn Debyle; Raymond Tsang; Alan J Parkinson
Journal:  Emerg Infect Dis       Date:  2008-01       Impact factor: 6.883

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307
View more
  5 in total

1.  Blood-Brain Barrier in a Haemophilus influenzae Type a In Vitro Infection: Role of Adenosine Receptors A2A and A2B.

Authors:  N Caporarello; M Olivieri; M Cristaldi; M Scalia; M A Toscano; C Genovese; A Addamo; M Salmeri; G Lupo; C D Anfuso
Journal:  Mol Neurobiol       Date:  2017-09-18       Impact factor: 5.590

2.  Measurement of Haemophilus influenzae type a capsular polysaccharide antibodies in cord blood sera.

Authors:  Daniel S Schmidt; Kathryn T Bieging; Patricia Gomez-de-León; Alberto Villaseñor-Sierra; Jaime Inostroza; John B Robbins; Rachel Schneerson; George M Carlone; Sandra Romero-Steiner
Journal:  Pediatr Infect Dis J       Date:  2012-08       Impact factor: 2.129

3.  Naturally acquired antibodies against Haemophilus influenzae type a in Aboriginal adults, Canada.

Authors:  Eli B Nix; Kylie Williams; Andrew D Cox; Frank St Michael; Sandra Romero-Steiner; Daniel S Schmidt; William G McCready; Marina Ulanova
Journal:  Emerg Infect Dis       Date:  2015-02       Impact factor: 6.883

4.  Characterization of natural bactericidal antibody against Haemophilus influenzae type a in Canadian First Nations: A Canadian Immunization Research Network (CIRN) Clinical Trials Network (CTN) study.

Authors:  Eli B Nix; Joshua Choi; Christina Anthes; Gabrielle N Gaultier; Joelle Thorgrimson; Andrew D Cox; Raymond S W Tsang; William G McCready; Douglas Boreham; Marina Ulanova
Journal:  PLoS One       Date:  2018-08-15       Impact factor: 3.240

5.  A Novel Luminescence-Based Serum Bactericidal Assay for Vibrio cholerae Reduces Assay Variation, Is Time- and Cost-Effective, and Directly Measures Continuous Titer Values.

Authors:  Taylor A Wahlig; Ben J Brintz; Melanie Prettyman; Andrew S Azman; Daniel T Leung
Journal:  Am J Trop Med Hyg       Date:  2021-07-08       Impact factor: 2.345
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.